Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

Completed · Phase 1 · Has a placebo group

Conditions studied: Skin Aging, Skin Wrinkling

In brief

The goal of this split-face clinical trial is to test the efficacy of microtox in improving facial skin quality, fine wrinkles, and texture. Participants will: * be randomly assigned to Group A (which will receive 20 units of neuromodulator on the left side of the forehead and a placebo saline treatment on the right side) or Group B (which will receive 20 units of neuromodulator on the left side of the forehead and 20 units of a different neuromodulator brand on the right side as a comparator) * have one treatment session at week 0, and two live assessment visits at weeks 2 and 12 * have their pictures taken at each visit to track progress

Key facts

Study ID

NCT06604832

Run by

Kalpna Kay Durairaj, MD, FACS

People needed

20

Starts

2024-09-03

Expected to finish

2025-09-16

Last updated by the study team

2025-10-21

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Biological females, 18-65 years old, of any race and ethnic background
• Individuals with mild to moderate facial wrinkles
• All skin types (Fitzpatrick I-VI)
• Willingness to participate and provide written informed consent
• Ability to follow study instructions and likely to complete all required visits

You may not qualify if…

• Females who are pregnant, breastfeeding, chronically using nonsteroidal anti-inflammatory drugs, have autoimmune conditions or have a known allergy to the study medications.
• Previous cosmetic procedures near the forehead within the last 6 months or botulinum toxin treatments within the last 4 months
• Known neuromuscular disorders or a hypersensitivity to botulinum toxin
• Significant dermatological conditions affecting the face
• Use of medications affecting neuromuscular function or skin healing within 2 weeks prior to the beginning of study
• Subject has a condition or is in a situation which, in the opinion of the Investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with participation in the study.

Where it is running

• K. Kay Durairaj, MD, A Medical Corp. — Pasadena, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.